Rutgers & Horizon plan to commercialize CRISPR base editing technology
Category: #health  By Saipriya Iyer  Date: 2019-01-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

Rutgers & Horizon plan to commercialize CRISPR base editing technology

Horizon has also agreed to fund further research in base editing at the Rutgers University.

Horizon Discovery Group plc, one of the globally reputed gene editing industry contenders, has reportedly inked a partnership with The State University of New Jersey, Rutgers. As per reliable sources, the agreement has been forged for developing and commercializing a gene editing technology – called base editing, that finds applications in new cell therapy development and is expected to augment Horizon’s research tools and services.

Credible reports cite that Horizon will join hands with the Rutgers University to develop the novel base editing platform from Dr. Shengkan Jin laboratory. As a part of the agreement, Horizon has already made a non-material payment to Rutgers, garnering the option to exclusively license the base editing technology to be used in all therapeutic applications. Sources familiar with the knowledge of the matter also claim that Horizon will fund further research in base editing at the Rutgers University while simultaneously undertaking evaluation and proof-of-concept studies at Horizon.

A report published by Genomeweb claims Terry Pizzie, CEO, Horizon, to have stated that base editing is one of the most potentially transformative of all gene editing technologies and is equipped with the ability to target numerous diseases that so far have no treatment. As a global leader in the field of gene modulation and gene editing, both in the applied as well as research markets, Horizon is rather thrilled to join forces with the Rutgers University, Pizzie added.

Further commenting on the partnership, Pizzie said that by extending Horizon’s scientific and IP capabilities, the company will now be more than able to completely support its pharma, academic, and biotech partners to deliver enhanced cell therapy solutions to patients. Also, as a part of its five-year investment strategy, Horizon is committed to pouring in capital in high-grade technologies which maintain its market leadership – base editing technology being the case in point, he elaborates.



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Compass Therapeutics announces first-in-human Phase 1 trial of CTX-471
Compass Therapeutics announces first-in-human Phase 1 trial of CTX-471
By Saipriya Iyer

CTX-471 has shown promising preclinical data, which include total eradication of established tumors in syngeneic mouse models.

Compass Therapeutics, a clinical-stag...

Amazon.in bets big on grocery category, expands Pantry to 110 cities
Amazon.in bets big on grocery category, expands Pantry to 110 cities
By Saipriya Iyer

Amazon Pantry expanding its footprint in smaller cities of India. The service was available over 40 cities in November 2018.

E-commerce giant Amazon.in has recently...

Medtronic unveils results from first-in-human study for EV ICD systems
Medtronic unveils results from first-in-human study for EV ICD systems
By Saipriya Iyer

Medtronic plc has reportedly unveiled the results from a test study of its investigational extravascular ICD system, where a lead is positioned outside of the heart and veins to provide anti-tachycardia pacing therapy ...